View the NewsRx Library

Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Google 2009 PageRank: #2 Among Top Health News and Media Publications

Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology

Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals

Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This site complies with the HONcode standard for trustworthy health information:
verify here.

Search Results for Biogen Idec Inc

Filter Articles: Clinical News | Consumer News | Business News | All News | More Options

Results 1 - 20 Next >

Refine Search

Display Mode: Context | Summary

Acorda Therapeutics Reports Third Quarter 2009 Financial Results

2009 NOV 16 ... Advertising, Finance, Financial, Investing, Marketing, Analgesic, Anticonvulsant, Biogen Idec Inc., Biotechnology Business, Biotechnology Company, Clinical Trials, Drugs, FDA, Marketing ...

Subject: Acorda Therapeutics, Inc.

Price: $3.00

Alnylam Pharmaceuticals Reports Third Quarter 2009 Financial Results

2009 NOV 16 ... from Novartis, the National Institutes of Health (NIH), Cubist Pharmaceuticals, Inc., Biogen Idec Inc., InterfeRx™, research reagent and services licensees, and other sources. Research ...

Subject: Alnylam Pharmaceuticals, Inc.

Price: $3.00

Biogen Idec and Biovitrum Announce Decision to Advance Long-Acting Hemophilia B Therapy into a Registrational Trial

2009 NOV 2 ... Clinical Trials, Genetics, Hospitals, Pharmaceutical, Research, Science, Technology, Biogen Idec Inc., Biotechnology Business, Biotechnology Company, Biovitrum AB, Clinical Trial Research, ...

Subject: Biogen Idec

Price: $3.00

Biogen Idec Extends Offer to Acquire Facet Biotech Corporation for $14.50 Per Share in Cash

2009 NOV 2 ... Biogen Idec Inc. (NASDAQ:BIIB) announced that it has extended the tender offer by its wholly owned ...

Subject: Biogen Idec Inc.

Price: $3.00

Biogen Idec Reports Third Quarter 2009 Results

2009 NOV 2 ... Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, ...

Subject: Biogen Idec Inc.

Price: $3.00

Biogen Idec to Present at the 2009 Annual Credit Suisse Healthcare Conference

2009 NOV 23 ... reads: BIOGEN IDEC TO PRESENT AT THE 2009 ANNUAL CREDIT SUISSE HEALTHCARE CONFERENCE Biogen Idec Inc. (NASDAQ:BIIB) announced that its presentation at the 2009 Annual Credit Suisse ...

Subject: Biogen Idec Inc.

Price: $3.00

Biotech Takes It on the Chin in October

2009 NOV 16 ... a mixed bag for pharma, med devices and biotechs." Keywords: Amgen Inc., Biogen Idec Inc., Biotechnology Business, Biotechnology Company, Bone, Clinical Trial Research, Drug ...

Subject: Biotechnology Business

Price: $3.00

Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration

2009 NOV 16 ... Caliper invited pioneers in this field from Pfizer (PFE), Amgen (AMGN), and Biogen Idec (BIIB) to describe their analytical approaches for biologics characterization. ... Caliper Life Sciences, Inc. (NASDAQ:CALP), a leading provider of life sciences tools, presented at a training ...

Subject: Regulatory Actions

Price: $3.00

Elan to Highlight Tysabri Data in Crohn's Disease at the American College of Gastroenterology Annual Scientific Meeting

2009 NOV 2 ... and surveillance program. Keywords: , Health, Pharmaceutical, Other Health, Biogen Idec Inc., Biotechnology, Biotechnology Business, Biotechnology Company, Clinical Trial Research, ...

Subject: Elan Corporation, plc and Biogen Idec

Price: $3.00

Genentech and Biogen Idec Receive a Complete Response from FDA for Earlier Use of Rituxan for Rheumatoid Arthritis

2009 NOV 2 ... Oncology, Optical, Pharmaceutical, FDA, Consumer, Food, Antirheumatic, Arthritis, Biogen Idec Inc., Biologics, Biotechnology, Biotechnology Business, Biotechnology Company, Blood Cancer, ...

Subject: Genentech, Inc.

Price: $3.00

ImmunoGen, Inc. Announces Election of Howard Pien to its Board of Directors and Other Results from its Annual Meeting of Shareholders

2009 NOV 23 ... with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III ... ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, ...

Subject: ImmunoGen, Inc.

Price: $3.00

ImmunoGen, Inc. Reports First Quarter Fiscal Year 2010 Financial Results

2009 NOV 9 ... Investing, Marketing, Technology, Amgen Inc., Anticancer Therapy, Bayer Healthcare AG, Biogen Idec Inc., Biotechnology, Biotechnology Business, Biotechnology Company, Biotest AG, Breast ...

Subject: ImmunoGen, Inc.

Price: $3.00

Instem Continues Global Growth Adding 12 New Clients, More Resources and More Offices

2009 NOV 1 ... Pharmaceutical, India, Advertising, Asia, China, Japan, Marketing, Software, Biogen Idec Inc., Biotechnology Business, Biotechnology Company, Clinical Trials, Cubist ...

Subject: Instem

Price: $3.00

Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roche's Actemra for Rheumatoid Arthritis

2009 NOV 16 ... of surveyed MCOs expect to cover its competitors, Genmab/GlaxoSmithKline's Arzerra and Biogen Idec/Roche's ocrelizumab, respectively. The Rheumatoid Arthritis Biologics ... clinical, economic and scientific factors. Keywords: Adalimumab, Amgen Inc., Arthritis, Biologics, Biotechnology, Clinical Trial Research, Drugs, Enbrel, ...

Subject: Arthritis

Price: $3.00

PanGenetics Announces Acquisition by Abbott of PG110 anti-NGF Antibody to Treat Chronic Pain

2009 NOV 23 ... Analgesia, Arthritis, Autoimmune Diseases, Autoimmune Disorder, Back Pain Relief, Biogen Idec Inc., Biotechnology Business, Biotechnology Company, COX-2 Inhibitors, Cancer, Chronic Pain, ...

Subject: PanGenetics

Price: $3.00

Special Report: Can Innovation Supplant Convention in Sarcoidosis Treatment?

2009 NOV 2 ... TNF-a inhibitors. Emerging treatments: Celgene's apremilast, MondoBiotech/Biogen Idec's aviptadil, Centocor/Medarex's Stelara, ongoing academic research. ... has announced the addition of Decision Resources, Inc.'s new report "Special Report: Can Innovation Supplant Convention in Sarcoidosis ...

Subject: Research and Markets

Price: $3.00

Study shows MabThera maintenance treatment delays disease progression in patients with incurable lymphoma

2009 NOV 16 ... with MabThera have been recorded worldwide since its launch. Genentech and Biogen Idec co-market Rituxan in the United States, and Roche markets MabThera in the rest of ...

Subject: Follicular Lymphoma

Price: $3.00

Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn's Disease

2009 NOV 9 ... , Health, Biotechnology, Clinical Trials, Pharmaceutical, Marketing, Advertising, Biogen Idec Inc., Biotechnology, Biotechnology Business, Biotechnology Company, Clinical Trial Research, ...

Subject: Elan Corporation plc / Biogen Idec

Price: $3.00

Unigene Licenses Phase III Oral Calcitonin Program to Tarsa Therapeutics

2009 NOV 2 ... a worldwide development and marketing agreement for lead product lixivaptan with Biogen Idec. "The new company assembled by this investor syndicate includes an ... Unigene Laboratories, Inc. (OTCBB: UGNE) and Tarsa Therapeutics, Inc. announced that Unigene has licensed its ...

Subject: Unigene Laboratories, Inc. / Tarsa Therapeutics, Inc.

Price: $3.00

Virdante Pharmaceuticals Secures Funding to Improve Antibody-based Therapeutics for Autoimmune and Inflammatory Disorders

2009 NOV 9 ... Finance, Technology, Antiinflammatory, Autoimmune Disease, Autoimmune Disorder, Biogen Idec Inc., Biopharmaceuticals, Biotechnology Business, Biotechnology Company, Drug Development, ...

Subject: Virdante Pharmaceuticals

Price: $3.00

Results 1 - 20 Next >


Home \| Free Newsletters \| Products \| Article Library \| About Us \| Contact \| Privacy Policy \| Search \| Visit VerticalNews.com Copyright © 2009 NewsRx